HLS Therapeutics (HLS) Stock Forecast & Price Target

C$3.20

-0.01 (-0.31%)

(As of 09/6/2024 ET)

Stock Analysis Analyst Forecasts Chart Competitors Dividend Earnings Headlines Insider Trades

HLS Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 3 Analyst Ratings

Based on 3 Wall Street analysts who have issued ratings for HLS Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a buy rating for HLS.

Consensus Price Target

C$3.63
13.28% Upside

High Forecast	C$4.00
Average Forecast	C$3.63
Low Forecast	C$3.25

According to the 3 analysts' twelve-month price targets for HLS Therapeutics, the average price target is C$3.63. The highest price target for HLS is C$4.00, while the lowest price target for HLS is C$3.25. The average price target represents a forecasted upside of 13.28% from the current price of C$3.20.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	0 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	C$3.63	C$3.88	C$3.88	C$13.83
Forecasted Upside	13.28% Upside	-5.49% Downside	-16.08% Downside	137.96% Upside

Get HLS Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Ad Mode Mobile

Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳

45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.

Claim Exclusive 100% Bonus: $0.25/Share

HLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HLS Therapeutics Stock vs. The Competition

Type	HLS Therapeutics	Medical Companies
Consensus Rating Score	2.33	2.77
Consensus Rating	Hold	Moderate Buy
News Sentiment Rating	Negative News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/13/2024	Stifel Nicolaus 4 of 5 stars		Lower Target		C$3.75 ➝ C$3.25	+4.84%
5/10/2024	Raymond James 4 of 5 stars		Lower Target		C$5.00 ➝ C$4.00	-3.61%
2/6/2024	Clarus Securities 5 of 5 stars	G. Ulybyshev Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
11/9/2023	Stifel Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Keywood Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/17/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		C$21.75 ➝ C$17.50	+175,000,000.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:21 PM ET.

HLS Forecast - Frequently Asked Questions

What is HLS Therapeutics' forecast for 2024?: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for HLS Therapeutics is C$3.63, with a high forecast of C$4.00 and a low forecast of C$3.25.
Should I buy or sell HLS Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares.
Does HLS Therapeutics's stock price have much downside?: According to analysts, HLS Therapeutics's stock has a predicted downside of -3.33% based on their 12-month stock forecasts.
What analysts cover HLS Therapeutics?: HLS Therapeutics has been rated by research analysts at Stifel Nicolaus in the past 90 days.
Do Wall Street analysts like HLS Therapeutics more than its competitors?: Analysts like HLS Therapeutics less than other "medical" companies. The consensus rating for HLS Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLS compares to other companies.